Voyager Therapeutics, Inc.
NASDAQ:VYGRBiotechnology
+$0.09 today
- Market cap
- $103.92M
- Beta
- 1.25
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$1.96
Volume 0.84M
Average 0.54M
VYGR Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Voyager Therapeutics, Inc.NASDAQ: VYGR
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin narrows to -1077.4%
Net margin was -1077.4% in Q1 FY2026, down 598.2 pp from a year earlier. On a trailing-twelve-month basis it was -319.6%, down 193.1 pp year over year. Over 3 fiscal years it narrowed by 183.1 pp.
Context
- Net margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 7 analysts of -453.6% for the fiscal year ending Dec 2026, down from -296.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -1077.4%-898.6 pp QoQ
- Last fiscal yearDec 2025
- -296.5%-215.3 pp YoY
- LTMMar 2026
- -319.6%-193.1 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -296.5%
- Year-over-year change
- -215.3pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -296.5% | -215.3pp |
| FY2024 | 2024-12-31 | -81.3% | -134.2pp |
| FY2023 | 2023-12-31 | 52.9% | +166.4pp |
| FY2022 | 2022-12-31 | -113.4% | +76.8pp |
| FY2021 | 2021-12-31 | -190.3% | — |
Net Margin vs competitors
How VYGR compares with its peers on the latest reported figures
- VYGR's LTM Mar 2026 net margin of -319.6% is the 4th highest of the 7 companies compared; the peer median is -381.6%.
- Its year-over-year change of -193.1 pp is the 4th highest of 6, against a peer median of -123.0 pp.
- Over three fiscal years its change of -183.1 pp compares with a peer median of -103.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -89.6% | +60.0 pp | +16.0 pp | |
| LTM Mar 2026 | -110.0% | -88.0 pp | -104.5 pp | |
| LTM Mar 2026 | -173.5% | -123.0 pp | -102.4 pp | |
| LTM Mar 2026 | -319.6% | -193.1 pp | -183.1 pp | |
| LTM Mar 2026 | -589.8% | — | — | |
| LTM Mar 2026 | -2895.1% | -2909.4 pp | — | |
| LTM Mar 2026 | -4840.8% | -3838.0 pp | -1239.0 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
SGMTSagimet Biosciences Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding VYGR) | -381.6% | -123.0 pp | -103.4 pp | |
Competitors are the stored peer set for VYGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.42M | 40.91M | 250.01M | 80M | 40.37M |
| Cost of Revenue | 73.79M | 55.76M | 92.17M | 0 | 0 |
| Gross Profit | (36.37M) | (14.86M) | 157.84M | 80M | 40.37M |
| Gross Margin | -97.2% | -36.3% | 63.1% | 100.0% | 100.0% |
| Research & Development | 73.79M | 60.76M | 92.17M | 127.37M | 134.67M |
| Selling, General & Admin | 37.25M | 30.98M | 35.82M | 35.92M | 37.54M |
| Operating Expenses | 37.25M | 35.98M | 35.82M | 163.29M | 172.22M |
| Depreciation & Amortization | 5.17M | 6.19M | 4.44M | 4.73M | 4.06M |
| EBITDA | (66.03M) | (39.65M) | 138.18M | (59.61M) | (115.52M) |
| EBITDA Margin | -176.5% | -96.9% | 55.3% | -74.5% | -286.1% |
| Operating Income | (73.62M) | (50.84M) | 122.01M | (83.29M) | (131.84M) |
| Operating Margin | -196.8% | -124.3% | 48.8% | -104.1% | -326.6% |
| Interest Income | 0 | 1.79M | 11.72M | 18.33M | 10.62M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 2.42M | 4.45M | 11.72M | 18.95M | 12.27M |
| Income Before Tax | (71.2M) | (46.39M) | 133.74M | (64.34M) | (119.58M) |
| Pre-Tax Margin | -190.3% | -113.4% | 53.5% | -80.4% | -296.2% |
| Income Tax Expense | 0 | 16K | 1.41M | 665K | 144K |
| Net Income | (71.2M) | (46.41M) | 132.33M | (65M) | (119.72M) |
| Net Margin | -190.3% | -113.4% | 52.9% | -81.3% | -296.5% |
| EPS (Basic) | (1.75) | (1.21) | 3.08 | (1.13) | (2.04) |
| EPS (Diluted) | (1.75) | (1.21) | 2.97 | (1.13) | (2.04) |
| Weighted Avg Shares | 37.67M | 38.36M | 43.02M | 57.67M | 58.69M |
| Weighted Avg Shares (Diluted) | 37.67M | 38.36M | 44.57M | 57.67M | 58.69M |
Voyager Therapeutics, Inc.
NASDAQ:VYGR
Intrinsic Alpha fair value
Locked
Current Price
$1.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.